Completed enrollment in the fourth cohort of the Phase 1b multiple-ascending dose (MAD) clinical trial of RGLS8429 for the treatment of autosomal dominant polycystic kidney disease (ADPKD) Presented a poster highlighting data from the ongoing MAD study of RGLS8429 in ADPKD at American Society of Nephrology (ASN) Kidney Week On track for an End-of-Phase 1 meeting by year-end Ended third quarter 2024 with cash, cash equivalents, and investments of $87.3 million; Cash runway into H1 2026 SAN DIEGO, Nov. 7, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company"

SAN DIEGO, Oct. 8, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced it has completed enrollment of 26 patients in the fourth cohort in the Phase 1b MAD study of RGLS8429 for the treatment of ADPKD. "The completion of enrollment of our final cohort marks an important milestone as we near the end of our Phase 1b study. We have been pleased to see positive results from each of the prior three cohorts, showing c

SAN DIEGO, Aug. 28, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the Company will participate in the following investor conferences: Wells Fargo Healthcare Conference: Fireside chat on Wednesday, September 4, 2024, at 2:15 p.m. ETH.C. Wainwright 26th Annual Global Investment Conference: Fireside chat on Monday, September 9, 2024, at 10:00 a.m. ETThe live events and replays of the presentations will

Announced positive topline data from the third cohort of patients in the Phase 1b MAD study of RGLS8429 in autosomal dominant polycystic kidney disease (ADPKD) On track for an End-Of-Phase 1 meeting by year-end Appointed Rekha Garg, M.D., M.S., to Chief Medical Officer Ended second quarter 2024 with cash, cash equivalents, and investments of $95.9 million; Cash runway into H1 2026 SAN DIEGO, Aug. 8, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the second quarter ended June 30, 2024, and provided a

SAN DIEGO, Aug. 6, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that members of the management team will present at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13th at 8:30 a.m. ET. A replay of the live presentation will be available under "Events and Presentations" through the investor relations section of the Company's website at https://ir.regulusrx.com/events and archived f

SAN DIEGO, July 9, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the Company will participate in the following investor conferences: H.C. Wainwright Third Annual Kidney Virtual Conference: Fireside chat on Monday, July 15, 2024, at 10:30 a.m. ET (7:30 a.m. PT).JonesHealthcare Seaside Summit: Presentation on Monday, July 15, 2024, at 4:00 p.m. ET (1:00 p.m. PT).The Company will provide a corporate upd

Continued mechanistic dose response observed following completion of 3 mg/kg dose level based on urinary biomarker analyses Percent change from baseline in PC1 and PC2 demonstrated a dose response across all doses tested, with statistical significance seen at 3 mg/kg compared to placebo Exploratory imaging analyses indicated reduction in total kidney volume in 70% of patients dosed with 3 mg/kg  Fourth cohort enrollment underway  Company to hold conference call at 8:30am ET today SAN DIEGO, June 24, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "R

SAN DIEGO, June 4, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it expects to be added to the broad-market Russell 3000® Index and the Russell 2000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th. The annual Russell US Indexes reconstitut

SAN DIEGO, May 16, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer effective May 16, 2024. Dr. Garg previously served as the Company's Senior Vice President, Clinical Development and Regulatory. "Dr. Garg has been leading the development and regulatory teams since joining Regulus in 2022," said Jay Hagan, Chief Executive Officer of Regulus Th

Initiated the fourth cohort of patients in the Phase 1b multiple-ascending dose (MAD) clinical trial of RGLS8429 for the treatment of autosomal dominant polycystic kidney disease (ADPKD) Topline data from the third cohort of patients in the Phase 1b MAD study of RGLS8429 expected in mid-2024 Ended first quarter 2024 with cash, cash equivalents, and investments of $107.7 million; Cash runway into H1 2026 SAN DIEGO, May 9, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the first quarter ended March 31,

Continued mechanistic dose response observed following completion of 3 mg/kg dose level based on urinary biomarker analyses Percent change from baseline in PC1 and PC2 demonstrated a dose response across all doses tested, with statistical significance seen at 3 mg/kg compared to placebo Exploratory imaging analyses indicated reduction in total kidney volume in 70% of patients dosed with 3 mg/kg  Fourth cohort enrollment underway  Company to hold conference call at 8:30am ET today SAN DIEGO, June 24, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "R

Mechanistic dose response observed at a 2mg/kg dose level based on urinary biomarker analyses Encouraging exploratory results of imaging-based biomarkers with greatest reductions in total kidney volume seen in patients with the highest increases in PC1 and PC2 Cohort 3 fully enrolled with data readout anticipated in mid-2024; Cohort 4 screening to start in 2Q 2024 Company to hold conference call at 8:30am ET today SAN DIEGO, March 12, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced positive topline results from the second

Statistically significant increase in urinary polycystin 1(PC1) after treatment with RGLS8429 Urinary polycystin exhibits anticipated pharmacokinetics/pharmacodynamics (PK/PD) correlation in patients with ADPKD Company to hold conference call at 8:30 a.m. EDT today SAN DIEGO, Sept. 20, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced positive topline results from the first cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD.

Company announced first patient dosed in its Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429 in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) Company announced positive topline safety and pharmacokinetic (PK) data from its Phase 1 Single-Ascending Dose (SAD) study of RGLS8429 in healthy volunteers for the treatment of ADPKD   $4.5 million in net proceeds in At-the-Market (ATM) sale to a new institutional investor SAN DIEGO, Nov. 10, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial res

SAN DIEGO, Nov. 3, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it will report its third quarter 2022 financial results on Thursday, November 10, 2022, after the U.S. financial markets close. In connection with the earnings release, Regulus' management team will host a live conference call and webcast on the same day at 5:00 PM ET, to discuss the Company's financial results and provide a corporate u

IND accepted and first subject dosed in the Phase 1 Single-Ascending Dose (SAD) study of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) RGLS8429 granted Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) Scientific leadership strengthened with the appointment of Amin Kamel, Ph.D., as Vice President, Drug Metabolism and Pharmacokinetics (DMPK) SAN DIEGO, Aug. 11, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the second quarter ended Jun

SAN DIEGO, Aug. 4, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it will report its second quarter 2022 financial results on Thursday, August 11, 2022, after the U.S. financial markets close. In connection with the earnings release, Regulus' management team will host a live conference call and webcast on the same day at 5:00 PM ET, to discuss the Company's financial results and provide a corporate up

FDA Acceptance of Investigational New Drug (IND) Application for RGLS8429 for Autosomal Dominant Polycystic Kidney Disease (ADPKD) On track to initiate Phase 1 study in second quarter 2022 SAN DIEGO, May 12, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.  "The year is off to a great start as we continue to advance

SAN DIEGO, March 10, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced its financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.  "Last year was a transformational year for Regulus with the accomplishments in our ADPKD program including clinical validation of the target and the prioritization and advancement of our next generation compound RGLS8429," comme

SAN DIEGO, March 3, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it has scheduled its fourth quarter and year-end 2021 financial results conference call and webcast on Thursday, March 10, 2022, after the U.S. financial markets close. In connection with the earnings release, Regulus' management team will host a live conference call and webcast at 5:00 PM ET on Thursday, March 10, 2022, to discuss th

First patient dosed in second cohort of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) in Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429  R&D Day to discuss our ADPKD program to be held Wednesday, September 6th Strengthened leadership through appointments of Preston S. Klassen, M.D. as President and Head of Research & Development and Curtis A. Monnig, Ph.D. as Vice President of CMC SAN DIEGO, Aug. 8, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results and provided a corporate upd

SAN DIEGO, June 23, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced Preston S. Klassen, M.D., President and Head of Research & Development, has been appointed to the Company's Board of Directors. "We are delighted to have Dr. Klassen join our board during this exciting time for Regulus, as we advance the clinical development of RGLS8429 for the treatment of ADPKD," said Stelios Papadopoulos, Ph.D., Chairman

Appoints Preston S. Klassen, M.D., as President and Head of Research & Development Curtis A. Monnig, Ph.D., named Vice President of CMC SAN DIEGO, June 12, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the appointment of Preston S. Klassen M.D., M.H.S., to President and Head of Research and Development. Dr. Klassen brings over 20 years of experience in leadership roles in both large and small biopharmaceutical companies. In addition, the Company announced the appointment of Curtis A. Monnig, Ph.D., to Vice President of

SAN DIEGO, Dec. 12, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that Simos Simeonidis, Ph.D., member of the Board of Directors, has stepped down from the Board, due to the time requirements of his recent appointment as co-Chief Executive Officer and co-Chief Investment Officer at Ally Bridge Group. His resignation was effective December 6, 2022. "On behalf of the Board and the whole team at Regulus, I

Additional Preclinical Promotions Round Out Scientific Leadership SAN DIEGO, Nov. 29, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the appointments of Rekha Garg, M.D., M.S., to Senior Vice President, Clinical Development and Regulatory, and Claire Padgett, Ph.D. to Senior Vice President, Clinical Operations. The company also announced the promotion of Morgan Carlson, Ph.D., to Vice President, Biology and Edmund Lee, Ph.D., to Vice President, Translational Medicine. Lastly, the Company announced, Denis Drygin, Ph.D., h

SAN DIEGO, June 2, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the appointment of Amin Kamel, Ph.D., as Vice President, DMPK. In his role, Dr. Kamel will support clinical development, in particular advancement of the Company's lead candidate, RGLS8429, which is being developed for patients with autosomal dominant polycystic kidney disease (ADPKD). In connection with his hiring, Dr. Kamel received an opt

SAN DIEGO, Dec. 3, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the appointment of Mohammad Ahmadian, Ph.D., as Vice President, Chemistry and Pharmaceutical Development. In his role, Dr. Ahmadian will assist in managing research and development of the Company's drug candidates, including RGLS8429, which is being developed for patients with autosomal dominant polycystic kidney disease (ADPKD), and will add significant expertise to Regulus' existing scientific talent.

LA JOLLA, Calif., March 9, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the fourth quarter and year ended December 31, 2020 and provided a corporate update.  "Regulus finished the year on a high note", stated Jay Hagan, CEO of Regulus. "We advanced RGLS4326 into a Phase 1b study in ADPKD patients, achieved an enrollment milestone for RG-012 with Sanofi and its Phase 2 clinical study for the treatment of patients with Alport syndrome, and completed a private financing.  With the recent progress, w